Biosenic SA

BioSenic provides third quarter 2024 Business Update

28 Oct 2024 01:00:00 By Nasdaq GlobeNewswire

BioSenic S.A. : Transparency notification received from ABO Infinium Americas OpCo LTD.

06 Oct 2024 23:59:59 By Nasdaq GlobeNewswire

BioSenic announces that it has started to look for new assets, the securing of its financing for the coming months by means of an amendment to its convertible bond contract, a change to the composition of its board of directors

30 Sep 2024 01:05:00 By Nasdaq GlobeNewswire

BioSenic reports half year 2024 results

30 Sep 2024 00:00:00 By Nasdaq GlobeNewswire

Véronique Pomi-Schneiter stands down as BioSenic's Deputy CEO

17 Sep 2024 00:00:00 By Nasdaq GlobeNewswire

BioSenic S.A.: Transparency notification received from ABO Infinium Americas OpCo LTD.  

19 Aug 2024 00:00:00 By Nasdaq GlobeNewswire

Medsenic receives the intention to grant a key European patent from EPO, valuable for the therapeutic development of arsenic trioxide in relapsing-remitting multiple sclerosis

14 Aug 2024 00:00:00 By Nasdaq GlobeNewswire

Medsenic/BioSenic patent granted in Japan for more protection of its therapeutic platform

13 Aug 2024 11:00:00 By Nasdaq GlobeNewswire

BioSenic S.A. : Transparency notification received from ABO Infinium Americas OpCo LTD.

13 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

BioSenic S.A. : Transparency notification received from Mr François Rieger

19 Jul 2024 11:00:00 By Nasdaq GlobeNewswire

BioSenic releases new in-depth analysis of its positive phase 2 clinical data for optimal administration scheme for its next late-stage trial of arsenic trioxide (ATO) targeting cGvHD

18 Jul 2024 00:00:00 By Nasdaq GlobeNewswire

BioSenic S.A. : Transparency notification received from Véronique Pomi  

12 Jul 2024 11:00:00 By Nasdaq GlobeNewswire

Medsenic, subsidiary of BioSenic SA, extends key patent to the United States

05 Jul 2024 00:00:00 By Nasdaq GlobeNewswire

Medsenic, BioSenic’s subsidiary, signed a new set of licensing and commercialization agreements with Phebra PTY Ltd.

02 Jul 2024 00:00:00 By Nasdaq GlobeNewswire

BioSenic S.A. : Information on the total number of voting rights and shares

28 Jun 2024 00:00:00 By Nasdaq GlobeNewswire

BioSenic signs a new subscription agreement for a maximum of EUR 2.1M in convertible bonds

21 Jun 2024 11:00:00 By Nasdaq GlobeNewswire

The Enterprise Court of Nivelles approves the BioSenic restructuring plan  

14 Jun 2024 00:00:00 By Nasdaq GlobeNewswire

BioSenic to host Annual General Meeting on July 12, 2024

12 Jun 2024 00:00:00 By Nasdaq GlobeNewswire

BioSenic announces 2023 full year results

06 Jun 2024 14:05:13 By Nasdaq GlobeNewswire

BioSenic S.A. : Information on the total number of voting rights and shares

31 May 2024 00:00:00 By Nasdaq GlobeNewswire